Dyadic International (NASDAQ:DYAI) Stock Passes Below 50 Day Moving Average – What’s Next?

Shares of Dyadic International Inc. (NASDAQ:DYAI) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.82 and traded as low as $0.76. Dyadic International shares last traded at $0.7701, with a volume of 20,848 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dyadic International presently has an average rating of “Hold” and an average target price of $3.00.

Dyadic International Trading Up 2.5%

The firm has a market capitalization of $28.06 million, a price-to-earnings ratio of -3.08 and a beta of 1.18. The business has a 50-day moving average of $0.82 and a two-hundred day moving average of $0.90. The company has a quick ratio of 2.68, a current ratio of 2.68 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, March 25th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $1.34 million. Dyadic International had a negative net margin of 239.67% and a negative return on equity of 695.96%. Research analysts predict that Dyadic International Inc. will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

A number of institutional investors have recently added to or reduced their stakes in DYAI. Marathon Capital Management acquired a new stake in Dyadic International during the third quarter valued at approximately $41,000. Bank of America Corp DE boosted its holdings in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International during the third quarter valued at approximately $190,000. Geode Capital Management LLC boosted its holdings in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Finally, Truist Financial Corp boosted its holdings in Dyadic International by 30.5% during the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares in the last quarter. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.